Back to search
Mixed Hepatocellular-cholangiocarcinoma
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Mixed Hepatocellular-cholangiocarcinoma trials may be worth asking aboutClinical trial pipeline · Data from ClinicalTrials.gov
See which Mixed Hepatocellular-cholangiocarcinoma trials may be worth asking aboutNorth America
Europe
Asia-Pacific
Rest of World
Trials may have sites in multiple countries. Filtering shows any trial with at least one site in the selected country.
The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with…
To evaluate HAIC combined with Camrelizumab plus rivoceranib for advanced mixed hepatocellular-cholangiocarcinoma (HCC-CCA).
The aim of this French multicenter retrospective study is to describ rare primary hepatic cancers clinical, histological and radiological features, to obtain a…
This study focused on exploring new comprehensive treatment strategies for patients with unresectable combined hepatocellular-cholangiocarcinoma, classifying pa…
The aim of this study is to reduce the length of stay after liver surgery by taking account of objective quantitative clinical variables, subjective qualitative…
This phase II trial compares the effect of adding bevacizumab and atezolizumab to gemcitabine and cisplatin (chemotherapy) versus chemotherapy and atezolizumab…